The report noted that among utilities, NVE shares displayed both attractive valuation metrics and strong profitability metrics.

FORBES: NVE's Strong Dividend History Helps Get It To The Top 10

Below is a long-term dividend history chart for NVE, which Dividend Channel stressed as being of key importance.

FORBES: NVE's Strong Dividend History Helps Get It To The Top 10

But since the FDA moved to ban ephedra, the suit says, NVE's sales of these products have comprised less than 5% of total sales.

FORBES: The Ephedra Battle Moves To The Courts

Stacker 2, the reputed herbal "fat burner" sold by privately held NVE Pharmaceuticals , can tell its story however it wants, big pharmaceutical companies face restrictions.

FORBES: Magazine Article

NVE's suit, filed in the U.S. District Court for the District of New Jersey, asks for the court to set aside the ban because it violates the 1994 law.

FORBES: The Ephedra Battle Moves To The Courts

Shares of NVE have tripled in value since June.

FORBES: Motorola Rolls In The Wrong Direction